NCI-H460

NCI-H460 is a cell line derived from a human lung cancer patient. It is commonly used in biomedical research to study the biology of lung cancer and to test potential therapeutic strategies.

History

The NCI-H460 cell line was established in 1982 from the pleural effusion of a 64-year-old Caucasian male with large cell carcinoma of the lung. The cell line was developed by the National Cancer Institute (NCI), hence the "NCI" in its name. The "H" stands for human, and "460" is the specific identifier for this cell line.

Characteristics

NCI-H460 cells are large and round with a diameter of about 20 micrometers. They grow in a monolayer and have a high mitotic index, which means they divide rapidly. This makes them useful for studies that require a large number of cells.

The cells express several markers that are characteristic of lung cancer, including epidermal growth factor receptor (EGFR), Keratin 18, and carcinoembryonic antigen (CEA). They also have a mutation in the KRAS gene, which is common in lung cancer.

Use in Research

NCI-H460 cells are used in a wide range of research applications. They are often used to study the biology of lung cancer, including the role of various genes and proteins in the disease. They are also used to test potential therapeutic strategies, including chemotherapy drugs and targeted therapies.

For example, researchers have used NCI-H460 cells to study the effects of EGFR inhibitors, which are a type of targeted therapy for lung cancer. They have also used the cells to test the efficacy of various chemotherapy drugs.

See Also

• Cell line
• Lung cancer
• National Cancer Institute
• Epidermal growth factor receptor
• KRAS

This cell line related article is a stub. You can help WikiMD by expanding it.